ANRO vs GH
ANRO: Alto Neuroscience is a clinical-stage biotech developing precision medicines for neuropsychiatric conditions by using biomarkers to match patients to targeted therapies. GH: Guardant Health is a precision oncology company transforming cancer care with FDA-approved blood and tissue tests powered by AI analytics that span early detection, treatment selection, and disease monitoring.
Side-by-side fundamentals
| Metric | ANRO | GH | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $27.23 | $150.75 | |
| Market cap as of 2026-07-23 | $1.0B | $19.8B | |
| PEG as of 2026-07-23 | -1.82 | -71.05 | GH lower |
| Net margin as of 2026-07-23 | -4374.8% | -40.1% | GH higher |
| Gross margin as of 2026-07-23 | n/a | +64.9% | |
| Operating margin as of 2026-07-23 | -5740.9% | -42.7% | GH higher |
| ROE as of 2026-07-23 | -47.2% | -246.6% | ANRO higher |
| ROA as of 2026-07-23 | -38.8% | -26.5% | GH higher |
| Debt / equity as of 2026-07-23 | 0.08 | 16.78 | ANRO lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +39.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +29.8% | |
| Beta as of 2026-07-23 | 2.32 | 1.63 | |
| 1-year return as of 2026-07-22 close | +891.6% | +225.9% | ANRO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.